An international collaboration has published groundbreaking research, shedding light on the most significant increase in complexity in the history of life's evolution on Earth: the origin of the ...

Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

It is important to recognize Kidney Cancer Awareness Month as a time to get involved, as more than 600,000 people in the U.S. live with kidney cancer. Looking back on March 2025, it is important to ...

INVESTIGATORS AND CLINICIANS anticipate that the next wave of therapeutic approaches in renal cell carcinoma (RCC) will target hypoxia-inducible factor-2 (HIF-2), a transcription factor that is ...

In 2016, 252,500 new cases of EC were diagnosed, and 193,900 patients died from EC in China (2). Squamous cell carcinoma (SCC) is the main histological subtype in China, making up around 90% of newly ...

Localised renal cell carcinoma (RCC) is usually treated surgically, with post-operative imaging-based surveillance to monitor for recurrence. However, surveillance practices vary widely, and patients ...

When these cells were transplanted into the kidneys of AKI mouse models induced by an anti-cancer drug, cisplatin, the animals' survival was vastly improved by preventing the deterioration of ...

Objective: Kidney-sparing surgery (KSS) has been increasingly performed in patients with upper tract urothelial carcinoma (UTUC) in recent years. We aim to conduct a systematic review and ...

Casdatifan, a novel HIF-2α inhibitor, demonstrated a 30% response rate in early trials for metastatic clear cell RCC. ctDNA is gaining attention for its potential role in personalized kidney cancer ...

The data come from an international study called AUR87A, which followed patients with clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. This disease subtype accounts for ...